leucine zipper and CTNNBIP1 domain containingGenealiases: []
Q-omics provides the consensus-scored LZIC profile across patient tissues and cancer cell-line models. LZIC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LZIC is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, LZIC RNA expression shows 19,502 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where LZIC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LZIC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LZIC survival associations across molecular data types. LZIC RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LZIC RNA expression–survival associations across cancer types. High LZIC expression shows unfavorable associations in ACC, KICH, BLCA, LGG and LIHC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LZIC RNA expression.
This table summarizes LZIC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LZIC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LZIC shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and BLCA. The HNSC box plot shows higher LZIC RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with LZIC in patient tissues and cancer cell lines. In patient samples, LZIC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LZIC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
